Cabaletta Bio, Inc.
NASDAQ: CABA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven A. Nichtberger
- Employees
- 161
- Headquarters
- Philadelphia, United States
- IPO year
- 2019
- Market cap
- $494.1M
- Website
- https://www.cabalettabio.com
Loading CABA…
Loading profile data…Frequently asked questions about CABA
What does Cabaletta Bio, Inc. (CABA) do?
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T...
Where does CABA trade?
Cabaletta Bio, Inc. (CABA) trades on the NASDAQ Global Select.
What sector is CABA in?
Cabaletta Bio, Inc. (CABA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cabaletta Bio, Inc.?
Steven A. Nichtberger is the chief executive officer of Cabaletta Bio, Inc. (CABA).
Where is Cabaletta Bio, Inc. headquartered?
Cabaletta Bio, Inc. is headquartered in United States.
Does CABA pay a dividend?
Cabaletta Bio, Inc. (CABA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CABA go public?
Cabaletta Bio, Inc. (CABA) completed its initial public offering in 2019.